Neuroscience-focused biopharmaceutical company Neurocrine Biosciences (Nasdaq:NBIX) on Thursday introduced INGREZZA SPRINKLE (valbenazine), a new sprinkle formulation of its treatment for tardive dyskinesia and chorea associated with Huntington's disease.
INGREZZA SPRINKLE provides an easier administration option for patients with swallowing difficulties, a common challenge for this patient group. The sprinkle capsules come in three dosages (40mg, 60mg, 80mg) and are designed to be easily opened with the contents sprinkled on soft food, such as applesauce, yogurt or pudding, for oral administration.
Neurocrine Biosciences received US Food and Drug Administration (FDA) approval for INGREZZA SPRINKLE in April 2024.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment